Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

AIM-HN/SEQ-HN : A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC

Male or<br/>FemaleGender Male or
Female

CompletedStatus Completed

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Head and Neck<br/>CancersCancer LocationHead and Neck
Cancers

Systemic therapy | Head and neckHead and neck,Nose (nasopharynx),Oropharynx,Voice box (larynx)

Trial Overview Read MoreRead more

This phase II trial is evaluating an oral systemic therapy in patients with HRAS positive Head and Neck Squamous Cell Carcinoma.
 

This trial is treating patients with Head and Neck Squamous Cell Carcinoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC

Commercial Sponsor

Kura Oncology, Inc.

Summary

The first study cohort, named AIM-HN, will include patients with HRAS mutated Head and Neck Squamous Cell Carcinoma (HNSCC) HRAS. Patients enrolled in AIM-HN, will receive treatment with tipifarnib, Dose Level 1 orally, on days 1-7 and 15-21 of 28-day treatment cycles. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in AIM-HN (HRAS mutant HNSCC) subjects in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.

Not Recruiting Hospitals Read MoreRead more

Completed

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Monc C Co-Team Leads
PCCTU.MoncC@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next